[Use of sodium nucleinate in the therapy of schizophrenia].
A total of 102 patients with progressive forms of schizophrenia with a pronounced deficital symptomatology were treated. The dynamics of some indices of nonspecific reactivity (properdin, lysozyme, complement) were studied parallely. Yeast sodium nucleinate promotes a softening and reverse development of some deficital symptoms (mainly in an emotional-volutional sphere), decreasing the threshold of sensitivity to neuroleptics. When remission occurred, the immunological indices returned to normal.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000032:analysis; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000097:blood; D009696:Nucleic Acids / Q000627:therapeutic use*; D011414:Properdin / Q000032:analysis; D012313:RNA / Q000008:administration & dosage / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors
D014150:Antipsychotic Agents; D009696:Nucleic Acids; D011414:Properdin; D012313:RNA; D003165:Complement System Proteins; C013683:sodium nucleinate; D009113:Muramidase
Ispol'zovanie nukleinata natriia v terapii bol'nykh shizofrenieĭ.